[
    [
        {
            "time": "2023-10-15",
            "original_text": "Merck KGaA, Pfizer drug fails to meet endpoints in gastric cancer trial",
            "features": {
                "keywords": [
                    "drug",
                    "fails",
                    "endpoints",
                    "gastric",
                    "cancer",
                    "trial"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-15",
            "original_text": "Merck and Pfizer Provide Update on Phase III JAVELIN Gastric 100 Trial",
            "features": {
                "keywords": [
                    "Merck",
                    "Pfizer",
                    "Phase III",
                    "JAVELIN",
                    "Gastric",
                    "Trial"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-15",
            "original_text": "EMD Serono and Pfizer Provide Update on Phase III JAVELIN Gastric 100 Trial",
            "features": {
                "keywords": [
                    "EMD Serono",
                    "Pfizer",
                    "Phase III",
                    "JAVELIN",
                    "Gastric",
                    "Trial"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]